Highlights for August 2017

  1. Strides complete acquisition of Australia Business of Amneal Pharma
  2. India's Aurobindo Pharma, Intas in race to buy Mallinckrodt's US generic business
  3. Daiichi sankyo enters worldwide licensing agreement with Boston pharmaceuticals for a highly selective RET inhibitor for solid tumors
  4. Astrazeneca, Takeda ink Parkinson’s co-development deal
  5. CSL Behring buys Calimmune for early stem cell, gene therapy boost
  6. Jazz pays $75M for chance to buy into immunogen adcs
  7. Samsung jumps into novel drug R&D through Takeda deal
  8. Regenxbio to buy battered Dimension for gene therapies
  9. Chinese biotechs sign extensive I-O deal with Arcus Biosciences worth up to $816 million
  10. Mundipharma and cellact announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1
  11. Bile duct cancer candidate bought by Mundipharma in deal worth up to $250 million
  12. Dermira gains certain rights to Roche mab in up to $1.4 billion deal
  13. Takeda and cardurion pharmaceuticals launch cardiovascular development partnership
  14. Tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan
  15. China’s hitgen bags new drug discovery deal with Aduro

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.